Overview Financials News + Filings IR Vault Key Docs Charts Transactions Ownership Insiders
|
| In millions, except per share items | Dec-25-21 | Dec-26-20 | Dec-28-19 | Dec-29-18 | Dec-30-17 | Dec-31-16 | Dec-26-15 | Dec-27-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Healthcare distribution | 11,760.1 | 9,529.6 | 9,389.5 | 9,009.2 | 8,545.8 | 11,146.1 | 10,270.9 | 10,022.5 |
| Technology and value-added services | 640.9 | 514.3 | 515.1 | 408.4 | 337.6 | 425.6 | 358.8 | 348.9 |
| Other | | 75.3 | 81.3 | | | | | |
| Total revenues | 12,401.0 | 10,119.1 | 9,985.8 | 9,417.6 | 8,883.4 | 11,571.7 | 10,629.7 | 10,371.4 |
| Revenue growth [+] | 22.6% | 1.3% | 6.0% | 6.0% | -23.2% | 8.9% | 2.5% | 8.5% |
| Healthcare distribution | 23.4% | 1.5% | 4.2% | 5.4% | -23.3% | 8.5% | 2.5% | 8.5% |
| Technology and value-added services | 24.6% | -0.2% | 26.1% | 21.0% | -20.7% | 18.6% | 2.8% | 9.0% |
| Cost of goods sold | 8,728.8 | 7,304.9 | 6,894.9 | 6,506.9 | 6,136.8 | 8,345.2 | 7,622.8 | 7,460.1 |
| Gross profit | 3,672.3 | 2,814.2 | 3,090.9 | 2,910.7 | 2,746.7 | 3,226.5 | 3,007.0 | 2,911.3 |
| Gross margin | 29.6% | 27.8% | 31.0% | 30.9% | 30.9% | 27.9% | 28.3% | 28.1% |
| Selling, general and administrative | 2,812.7 | 2,246.8 | 2,357.9 | 2,217.3 | 2,071.6 | 2,409.0 | 2,238.1 | 2,196.2 |
| Equity in earnings | 20.0 | 12.3 | 17.9 | 21.0 | 15.3 | 18.5 | 14.1 | 11.7 |
| EBITDA [+] | 1,089.1 | 765.3 | 935.8 | 858.1 | 824.2 | 1,005.8 | 942.1 | 879.1 |
| EBITDA growth | 42.3% | -18.2% | 9.1% | 4.1% | -18.0% | 6.8% | 7.2% | 7.8% |
| EBITDA margin | 8.8% | 7.6% | 9.4% | 9.1% | 9.3% | 8.7% | 8.9% | 8.5% |
| Depreciation | 85.7 | 79.6 | 76.6 | 68.3 | 63.6 | 71.6 | 66.2 | 62.6 |
| EBITA | 1,003.4 | 685.6 | 859.2 | 789.8 | 760.7 | 934.2 | 875.9 | 816.5 |
| EBITA margin | 8.1% | 6.8% | 8.6% | 8.4% | 8.6% | 8.1% | 8.2% | 7.9% |
| Amortization of intangibles | 123.8 | 105.9 | 108.3 | 75.3 | 70.3 | 98.2 | 92.9 | 89.6 |
| EBIT [+] | 879.6 | 579.7 | 750.9 | 714.5 | 690.4 | 836.0 | 783.0 | 726.9 |
| EBIT growth | 51.7% | -22.8% | 5.1% | 3.5% | -17.4% | 6.8% | 7.7% | 5.8% |
| EBIT margin | 7.1% | 5.7% | 7.5% | 7.6% | 7.8% | 7.2% | 7.4% | 7.0% |
| Non-recurring items [+] | 7.9 | 32.1 | 14.7 | 92.9 | 5.3 | 45.9 | 34.9 | |
| Legal settlement | | | | 38.5 | 5.3 | | | |
| Interest expense, net [+] | 21.1 | 31.5 | 35.0 | 60.5 | 38.6 | 18.6 | 13.1 | 10.4 |
| Interest expense | 27.6 | 41.4 | 50.8 | 76.0 | 51.1 | 31.9 | 26.0 | 24.1 |
| Interest income | 6.5 | 9.8 | 15.8 | 15.5 | 12.4 | 13.3 | 12.9 | 13.7 |
| Other income (expense), net [+] | -20.0 | -16.2 | -20.8 | -24.3 | -16.6 | -15.6 | -14.2 | -7.2 |
| Gain (loss) on sale of assets | 7.3 | 1.6 | 186.8 | | -17.6 | | | |
| Other | 0.0 | -3.9 | -2.9 | -3.3 | -1.3 | 2.9 | -0.1 | 4.6 |
| Pre-tax income | 830.5 | 499.9 | 680.3 | 536.8 | 629.8 | 755.8 | 720.8 | 709.3 |
| Income taxes | -197.3 | -95.4 | -159.5 | 107.4 | -309.0 | 218.0 | 211.4 | 215.6 |
| Tax rate | | | | 20.0% | | 28.8% | 29.3% | 30.4% |
| Minority interest | | | | | | 49.6 | 44.4 | 39.4 |
| Earnings from continuing ops | 660.5 | 418.4 | 1,450.9 | 450.4 | 318.5 | 506.8 | 479.1 | 466.1 |
| Earnings from discontinued ops | | 1.0 | -6.3 | 111.7 | 140.8 | | | |
| Net income | 660.5 | 419.4 | 1,444.6 | 562.1 | 459.3 | 506.8 | 479.1 | 466.1 |
| Net margin | 5.3% | 4.1% | 14.5% | 6.0% | 5.2% | 4.4% | 4.5% | 4.5% |
| |
| Basic EPS [+] | $4.71 | $2.94 | $9.82 | $2.95 | $2.03 | $3.14 | $2.89 | $5.53 |
| Growth | 60.6% | -70.1% | 232.7% | 45.3% | -35.2% | 8.4% | -47.7% | 10.1% |
| Diluted EPS [+] | $4.66 | $2.92 | $9.72 | $2.93 | $2.01 | $3.10 | $2.85 | $5.44 |
| Growth | 59.7% | -70.0% | 231.7% | 45.6% | -35.0% | 8.7% | -47.6% | 10.4% |
| |
| Shares outstanding (basic) [+] | 140.1 | 142.5 | 147.8 | 152.7 | 156.8 | 161.6 | 165.7 | 84.3 |
| Growth | -1.7% | -3.6% | -3.2% | -2.6% | -3.0% | -2.4% | 96.6% | -1.9% |
| Shares outstanding (diluted) [+] | 141.8 | 143.4 | 149.3 | 153.7 | 158.2 | 163.7 | 168.3 | 85.7 |
| Growth | -1.1% | -3.9% | -2.9% | -2.8% | -3.4% | -2.7% | 96.2% | -2.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|